Status:
COMPLETED
PET MRI in Coronary Artery Disease
Lead Sponsor:
University of Edinburgh
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
40+ years
Brief Summary
This study will assess the use of position emission tomography/magnetic resonance imaging (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast agent in patients ...
Detailed Description
Positron emission tomography/magnetic resonance imaging (PET/MRI) has the potential to provide detailed information on coronary artery anatomy, the presence of coronary artery stenosis, the compositio...
Eligibility Criteria
Inclusion
- Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to provide informed consent.
- Patients with coronary artery disease to undergo PET/MRI will have multi-vessel disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal stenosis).
- able to provide informed consent
- over the age of 40 years
Exclusion
- inability or unwillingness to undergo magnetic resonance imaging or positron emission tomography
- renal failure (Serum creatinine \>200 umol/L or estimated glomerular filtration rate \<30 mL/min
- hepatic failure
- pregnancy
- inability to provide informed consent
- contraindications to undergoing MRI scanning
- contraindications to contrast agents not included above including evidence of iron overload, known allergy to constituents of the contrast agents, and anaemia not caused by iron deficiency
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03451448
Start Date
February 1 2018
End Date
January 31 2024
Last Update
May 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom